A Phase II Clinical Study of Treatment With Disitamb Vedotin Plus Pyrotinib in HER2-positive Early Breast Cancer

Evaluate the efficacy and safety of Disitamb Vedotin combined with pyrotinib in HER2 positive early breast cancer

Trial Details

NCT ID
NCT06001086
Phase
PHASE2
Sponsor
The First Affiliated Hospital with Nanjing Medical University
Status
RECRUITING
Cancer Type
HER2 Positive Breast Cancer
Interventions
  • Disitamb Vedotin ,pyrotinib
Locations (sample)
  • Nanjing, Jiangsu, China|32.06167,118.77778

Key Eligibility Criteria

  • 18 to 75 years old (at the time of signing the informed consent form), regardless of gender.
  • 2\. Subject type and disease characteristics. Histologically confirmed HER2 positive EBC subjects:
  • evaluated as HER2 positive in local laboratories according to ASCOCAP guidelines.
  • Single and multifocal tumors (greater than 1 tumor area limited to the same quadrant as the primary tumor) must be sampled from 1 lesion and labora…

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find HER2 Positive Breast Cancer Trials on Trialify →